PYXS
HEALTHCAREPyxis Oncology Inc
$2.30+0.47 (+25.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PYXS Today?
No stock-specific AI insight has been generated for PYXS yet. However, PYXS was mentioned in the following AI insights:
52-Week Range
$0.97$5.55
$2.30
Fundamentals
Market Cap$145M
P/E Ratio—
EPS$-1.28
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding62.9M
PYXS News
20 articles- Pyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerYahoo Finance·May 7, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026Yahoo Finance·Apr 17, 2026
- 3 Penny Stocks With Market Caps Under $400M To ConsiderYahoo Finance·Apr 13, 2026
- Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 23, 2026
- 3 Penny Stocks With Market Caps Over $50M To WatchYahoo Finance·Feb 6, 2026
- Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program ContinuityYahoo Finance·Feb 3, 2026
- 3 Promising Penny Stocks With Market Caps Up To $300MYahoo Finance·Jan 7, 2026
- Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims DeclineYahoo Finance·Dec 18, 2025
- Investors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-BellYahoo Finance·Dec 18, 2025
- Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaYahoo Finance·Dec 18, 2025
- 3 Promising Penny Stocks With Over $90M Market CapYahoo Finance·Dec 9, 2025
- Pyxis Oncology And 2 Other Promising Penny Stocks To WatchYahoo Finance·Nov 4, 2025
- Pyxis Oncology to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 3, 2025
- Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 3, 2025
- Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus TherapeuticsYahoo Finance·Oct 15, 2025
- Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance·Oct 14, 2025
- 5 Small Drug Stocks to Buy as the Industry Shows Some RecoveryYahoo Finance·Oct 14, 2025
- Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical MeetingsYahoo Finance·Oct 13, 2025
- Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital MarketsYahoo Finance·Oct 9, 2025
All 20 articles loaded
Price Data
Open$1.85
Previous Close$1.83
Day High$1.99
Day Low$1.82
52 Week High$5.55
52 Week Low$0.97
52-Week Range
$0.97$5.55
$2.30
Fundamentals
Market Cap$145M
P/E Ratio—
EPS$-1.28
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding62.9M
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—